Log in or Sign up for Free to view tailored content for your specialty!
Sjögren’s Syndrome News
Trial of tivanisiran for dry eye associated with Sjögren’s fails to meet primary endpoint
A phase 3 clinical trial of tivanisiran failed to meet the primary endpoint in the treatment of dry eye disease associated with Sjörgren’s syndrome, according to a press release from Sylentis.
Topline VIVACITY, DAHLIAS data: Nipocalimab bests placebo for myasthenia gravis, Sjögren’s
Nipocalimab met the primary endpoint in a pivotal phase 3 trial in patients with generalized myasthenia gravis, as well as in a phase 2 study in adults with Sjögren’s disease, according to topline results released by Johnson & Johnson.
Log in or Sign up for Free to view tailored content for your specialty!
NIH grants Oklahoma Medical Research Foundation $5.8 million for Sjögren’s research
The Oklahoma Medical Research Foundation has received a $5.8 million award from the NIH for research into the diagnosis and management of Sjögren’s disease, according to a press release.
Best rheumatology Q&As of 2023 covered Alzheimer’s, lupus in a catatonic patient
In 2023, Healio had questions, the experts had answers.
IMIDomics, Bristol Myers Squibb to research Sjögren's disease, atopic dermatitis
IMIDomics and Bristol Myers Squibb have expanded their partnership to include Sjögren's syndrome and atopic dermatitis in their research and development efforts for inflammatory diseases, the companies announced in a press release.
Odds of opioid use in autoimmune rheumatic disease decreased 15% annually after 2014
SAN DIEGO — The likelihood of opioid use among patients with autoimmune rheumatic disease has decreased annually by 15% since 2014, according to data presented at ACR Convergence 2023.
Pregnant patients with low anti-Ro titers have ‘little to no’ risk for fetal heart block
SAN DIEGO — Pregnant patients with very low anti-Ro antibody titers of less than 1,000 units per mL have minimal-to-no risk for fetal atrioventricular block, according to data presented at ACR Convergence 2023.
FDA grants 510(k) clearance to Werfen’s reagent for connective tissue disease testing
The FDA has granted 510(k) clearance to Werfen for its Aptiva Connective Tissue Disease Essential reagent to assist in the diagnosis of patients with autoimmune diseases, according to a manufacturer press release.
Psychiatric symptom burden in SARDs higher, ‘more wide-ranging’ than previously recorded
The prevalence of neuropsychiatric symptoms in patients with systemic autoimmune rheumatic diseases is significantly “higher and more wide-ranging” than previously recognized, according to data published in Rheumatology.
Patients with inflammatory rheumatic disease at higher risk for severe COVID-19
Patients with inflammatory rheumatic diseases are as likely as the general population to contract COVID-19, but are at a higher risk for severe outcomes, including hospitalization and death, according to data.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read